Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7.
Papillomaviruses are etiological agents of epithelial proliferative disease. In man, neoplastic transformation of the uterine cervix has been linked to infection with specific subtypes of human papillomavirus, particularly types 16 and 18. We previously reported that live vaccinia virus recombinants expressing early transforming proteins of other tumor viruses can immunize against challenge with cognate tumor cells and we have extended this approach to HPV16. Neoplastic transformation by papillomaviruses involves expression of early open reading frames (ORFs) E5, E6, and E7, and we report the construction of vaccinia recombinants separately expressing ORFs E5-E7 of HPV16. Primary rat cell lines cotransformed with HPV16 and an activated ras oncogene were established in order to evaluate the potential of the recombinants to elicit antitumor immunity. We report that inoculation of rats with vaccinia recombinants expressing E6 or E7 retarded or prevented tumor development in a proportion of animals challenged by subcutaneous seeding of tumor cells whereas the recombinant expressing E5 was inactive.
Meneguzzi
G
G
U273-INSERM, Centre de Biochimie du CNRS, Nice, France.
Cerni
C
C
Kieny
M P
MP
Lathe
R
R
D000818:Animals; D001483:Base Sequence; D002471:Cell Transformation, Neoplastic; D005814:Genes, Viral; D011905:Genes, ras; D008969:Molecular Sequence Data; D015345:Oligonucleotide Probes; D016366:Open Reading Frames; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D051381:Rats; D011916:Rats, Inbred F344; D011995:Recombination, Genetic; D014162:Transfection; D014412:Tumor Virus Infections / Q000276:immunology*; D014616:Vaccinia virus / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage*
D015345:Oligonucleotide Probes; D014764:Viral Proteins; D014765:Viral Vaccines